Jazz Pharmaceuticals’ Luvox CR Gets Feb. 29 Action Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Company expects to launch the extended-release anti-anxiety medication in the first quarter, after FDA accepts response to “approvable” letter.
You may also be interested in...
Jazz/Solvay Gain Approval Of Luvox CR
Approval of anxiety/obsessive compulsive disorder drug comes a day ahead of its scheduled user fee date.
Jazz/Solvay Gain Approval Of Luvox CR
Approval of anxiety/obsessive compulsive disorder drug comes a day ahead of its scheduled user fee date.
Jazz Pharmaceuticals Gets Second “Approvable” Letter For Once-Daily Luvox
FDA seeks further information on chemistry, manufacturing and controls for Luvox CR NDA.